Samsung Bioepis gets label supplement approved for Byooviz ranibizumab biosimilarSep 1Regulatory decisionBiogenHarrow Inc
Outlook Therapeutics posts Phase 3 results for ONS-5010 in wet AMD trialAug 3Trial updatebevacizumabOutlook Therapeutics, Inc.
Outlook Therapeutics posts NORSE EIGHT phase 3 results for ONS-5010 in wet AMDJun 30Trial updatebevacizumabOutlook Therapeutics, Inc.
Sign inSign in